Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.
Source: US Top News and Analysis
Related Posts
JPMorgan sees more upside for this AI data center play, fueled by ‘exceptional earnings growth’
Lumentum is likely to see its shares rise thanks to the high-speed networking equipment, 3D…
Rethinking electric vehicles, as gas prices surge? See the best hybrid and EV car insurance of April 2026
These hybrid and electric car insurance policies offer discounts and bundling options to cut costs.…
This morning routine is key to a successful day, says mental performance coach—and it only takes 4 minutes
Start the day strong by focusing on gratitude and purpose, says mental performance coach Cindra…